Form 4: Opko Health Sells GeneDx Holdings Corp. Shares in Multiple Transactions

Opko Health, a 10% owner of GeneDx Holdings Corp., sold a significant number of Class A Common Stock shares over two days in August 2024.

Summary

• Opko Health, identified as a 10% owner of GeneDx Holdings Corp., filed a Form 4 indicating changes in beneficial ownership.
• On August 12, 2024, Opko Health sold 59,787 shares of Class A Common Stock at a weighted average price of $33.9507, with individual transactions ranging from $33.16 to $34.90.
• Following this transaction, Opko Health beneficially owned 2,811,783 shares.
• On August 13, 2024, Opko Health sold an additional 24,987 shares of Class A Common Stock at a weighted average price of $34.7582, with individual transactions ranging from $34.50 to $35.9175.
• After the second transaction, Opko Health's beneficial ownership decreased to 2,786,796 shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting share sales. It doesn't inherently convey positive or negative sentiment, but the market's reaction to the sale could be either depending on the context.

Industry Context

This filing indicates a significant shareholder, Opko Health, is reducing its stake in GeneDx Holdings Corp., which could be related to Opko's investment strategy or GeneDx's performance and outlook within the genetic testing industry.

Comparison to Industry Standards

• It's difficult to assess the impact of these sales without knowing the overall trading volume and market capitalization of GeneDx Holdings Corp.
• Comparing these transactions to similar sales by major shareholders in comparable companies like Invitae or Myriad Genetics would provide a better benchmark.
• For example, if Invitae's major shareholders sold a similar percentage of their holdings, it would be considered a normal market activity.

Stakeholder Impact

• The share sales could potentially impact shareholder confidence and the stock price of GeneDx Holdings Corp.

Key Dates